US finalises guidance on biosimilars

The US Food and Drug Administration (FDA) has published much-anticipated guidance detailing what companies need to do to prove that their biosimilar products are interchangeable with the originator drug and can therefore be substituted at pharmacies like generic medicines. Industry appears pleased with the new guidelines, despite the increased competition they are intended (and expected) to create in the market.